"Man-in-the-plant", FDA's Failure to Regulate Deceptive Drug Labeling: Hearings Before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-fifth Congress, Second Session, September 8 and 12, 1978
United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 1978 - Drugs - 144 pages
10 pages matching ANDA in this book
Results 1-3 of 10
What people are saying - Write a review
We haven't found any reviews in the usual places.
6110 Robinwood Road Alex Jones amoxicillin trihydrate ANDA antibiotic approved April April 17 Baltimore Barr Laboratories brand name drug brand-name Bureau of Drugs CARTWRIGHT certification Chairman Checks and signs Chlordiazepoxide chlorpromazine COHEN Commissioner committee comprehensive inspection Consumer Safety Officer COOPER correct counsel Davis deceptive digitoxin distributor document Drug Administration drug applications drug manufacturing fiction firm Food and Drug Form 6 application GORE HADDAD HARRISON HEALTH IIADDAD KARPERS label LEAL lease Lederle Laboratories Lederle's legislation look man-in-the-plant policy manufacturing practices McENiRY memo methods and processes MOFFETT Moss Mylan Pharmaceuticals operation package Parke Parke-Davis penicillin Peter Barton plant priority problem procedures proposed question referred to follows regulation require response SEIFE specifications staff subcommittee submitted Susan Leal tablets testimony testing Thank tion trihydrate capsules Tutag WALGREN WUNDER Wyeth Wyeth Laboratories yield York State Assembly